



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/272,835	03/19/1999	FREDERIC J. DE SAUVAGE	P1268R1	6145

7590

04/09/2002

KNOBBE, MARTENS, OLSON & BEAR, LLP
620 NEWPORT CENTER DRIVE,
SIXTEENTH FLOOR
NEWPORT BEACH, CA 92660

EXAMINER

HAYES, ROBERT CLINTON

ART UNIT	PAPER NUMBER
----------	--------------

1647

DATE MAILED: 04/09/2002

21

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/272,835			

EXAMINER	
ART UNIT	PAPER NUMBER
	21

DATE MAILED:


Please find below a communication from the EXAMINER in charge of this application


Commissioner of Patents

The communication filed on **01/30/02** remains not fully responsive to the communication mailed **10/15/01** for the reason(s) set forth on the attached Notice to Comply With the Sequence Rules and/or *CRF Diskette Problem Report*. Secondly, 37 CFR 1.821 (a)(2)(d) still states that each sequence disclosed must appear separately in the "Sequence listing", and referenced appropriately *in the text of the description* and the claims; therefore, in order to clearly indicate what is being described in the specification, etc. See MPEP 2422 & 2431. In other words, although Applicant's arguments on page 5 of the response (paper #19) are persuasive for SEQ ID NO:20 as including the *murine* GFR α 3 sequence, page 54, line 3 merely states GFR α 3-IgG as SEQ ID NO:18 with no reference to it being a *human* sequence. The specification must be amended on page 54 to correctly describe SEQ ID NO:18 as being human. Note further that the amendment to page 49 of the specification from page 4 of paper #19 has eliminated any reference to SEQ ID NO:21, as required. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Since the response appears to be **bona fide**, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment under 37 CFR 1.821(g). EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a)

Any inquiry concerning this communication should be directed to Examiner **Robert C. Hayes**, Art Unit **1647**, whose telephone number is **703-305-3132**.


Robert C. Hayes, Ph.D.
April 8, 2002


GARY L. KUNZ
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600